Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
CRISPR Therapeutics AG manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 8 pending office actions. These actions are distributed across 8 distinct examiners and 8 distinct art units, reflecting a highly diversified prosecution strategy within the biotechnology sector.
The busiest examiner for the company is HOLLAND, PAUL J, who is responsible for 1 pending office action. Because there are 8 pending office actions and 8 distinct examiners, each examiner is currently handling exactly 1 action. The distribution across 8 distinct art units indicates a broad prosecution front, with each pending application being reviewed by a different specialized group within the patent office. This one-to-one ratio of actions to examiners and art units suggests that the company's biotechnology filings are technically distinct enough to be scattered across 8 different specialized units. For a practitioner, this means managing 8 separate examiner relationships and navigating the specific standards of 8 different art units for the company's 8 pending actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| LEONARD, ARTHUR S | 1 | 50.8% | +50.2% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 126d overdue |
| 18336961 | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY | YU, DELPHINUS DOU YI | — |
| 17933369 | UNIVERSAL DONOR CELLS | QIAN, CELINE X | — |
| 17489218 | MATERIALS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | YU, DAVID TUYANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 126d overdue |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 80d overdue |
| 18444368 | COMPOSITIONS AND METHODS FOR GENE EDITING | HOLLAND, PAUL J | 33d |
| 18482752 | GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES | FAUST, AMBER KATHLEEN | — |
| 17933369 | UNIVERSAL DONOR CELLS | QIAN, CELINE X | — |
| 17818673 | UNIVERSAL DONOR CELLS | LEONARD, ARTHUR S | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1643 | 1 |
| 1636 | 1 |
| 1637 | 1 |
| 1645 | 1 |
| 1631 | 1 |
| 1633 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18444368 | COMPOSITIONS AND METHODS FOR GENE EDITING | HOLLAND, PAUL J | 1656 | §103 | Final Rejection | 33d | Pending | Feb 16, 2024 |
| 18482752 | GENETICALLY ENGINEERED ANTI-CD19 CAR-T CELLS FOR USE IN TREATING B-CELL MALIGNANCIES | FAUST, AMBER KATHLEEN | 1643 | §103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18336961 | LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY | YU, DELPHINUS DOU YI | 1636 | §103§112Other | Non-Final OA | — | Pending | Jun 17, 2023 |
| 17933369 | UNIVERSAL DONOR CELLS | QIAN, CELINE X | 1637 | §103§112 | Final Rejection | — | Pending | Sep 19, 2022 |
| 17906471 | T-CELL BISPECIFIC BINDING PROTEINS | OGUNBIYI, OLUWATOSIN A | 1645 | §103§112 | Non-Final OA | 126d overdue | Pending | Sep 15, 2022 |
| 17818673 | UNIVERSAL DONOR CELLS | LEONARD, ARTHUR S | 1631 | Other | Final Rejection | — | Pending | Aug 09, 2022 |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103Other | Non-Final OA | 80d overdue | Pending | Oct 01, 2021 |
| 17489218 | MATERIALS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | YU, DAVID TUYANG | 1600 | §102§103§112 | Non-Final OA | — | Pending | Sep 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial